speb/financial-data huggingface dataset:
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 3040000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 11720000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 3420000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Normalized Income: 4148000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 1370000000.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 7810000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Operating Income: 6770000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Operating Income: 2160000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Operating Revenue: 82860000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 22050000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 362594369.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 362594369.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 3670000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 3670000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 690000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 690000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 57740000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 57740000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 2540000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 2540000000.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 3360000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 800000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 800000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 700000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 700000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 50000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -10000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 13640000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 4460000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Properties: 63020000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 63020000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 50000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 50000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 840000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 840000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Payables: 18400000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Payables: 18400000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Pretax Income: 3650000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 1110000000.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -640000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 53490000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 13210000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 4740000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 1190000000.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -2420000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Share Issued: 362594369.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 362594369.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Special Income Charges: 70000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 100000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 59550000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 59550000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 57010000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 57010000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 28000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Tax Provision: -540000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Tax Provision: -260000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.40
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 130000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 130000000.00
AARTIIND.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: 30000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Assets: 132990000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 132990000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 81430000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 81430000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Debt: 49660000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 49660000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 59550000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 59550000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Total Expenses: 76090000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 19890000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 73440000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 73440000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 91120000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 91120000000.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 23060000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 23060000000.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 70000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
AARTIIND.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 70000000.00
AARTIIND.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIIND.NS balance_sheet (annual, 2026-03-31) — Working Capital: -8510000000.00
AARTIIND.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: -8510000000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -4051070000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 4403254000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 1261297000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 563062000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 269672000.00
AARTIPHARM.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: -260223.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 1902178000.00
AARTIPHARM.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: -25187000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 15084000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Interest Income: 57000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 57000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Investments In Other Ventures Under Equity Method: 285522000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 649853000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 285522000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 9940805000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 85842000.00
AARTIPHARM.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: 16000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 21945000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Other Special Charges: -208000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 87834000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 41955000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
AARTIPHARM.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: -1132000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 1929766000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 1151000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 1151000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 0.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 7172365000.00
AARTIPHARM.NS cash_flow (annual, 2022-03-31) — Sale Of Investment: 401000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 261364000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 276448000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 116186000.00
AARTIPHARM.NS balance_sheet (annual, 2022-03-31) — Work In Process: 900648000.00
AARTIPHARM.NS income_statement (annual, 2022-03-31) — Write Off: 70000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — +Operating Expense: 4025278000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — +Total Revenue: 19360045000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 3395021000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 4501038000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -4675670000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 4405754000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -25000000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Amortization: 443000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 443000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 298630000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 90626008.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Basic EPS: 21.35
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 832734000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1635436000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -1196569000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 9767000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 453130000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 121212000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 631113000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -181252000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 128085000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 121212000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -1266622000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Change In Payable: 1302026000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -351719000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -316315000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -711522000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock: 453130000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 15584866000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 646980000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 12539679000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Assets: 11630059000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 4448000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt: 2141526000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 2145974000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 6006234000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 112143000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation: 624984000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 625427000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 625427000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 624984000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 90626008.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Diluted EPS: 21.35
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 1934934000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 723000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 400000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — EBIT: 2818265000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — EBITDA: 3443692000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — End Cash Position: 121212000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -1634646000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 2653112000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 1304585000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -8022000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 144393000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 416303000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 4526038000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 14561394000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Gross Profit: 6820366000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense: 210517000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 210517000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Interest Income: 9373000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 9373000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -210517000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 9373000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Inventory: 6020410000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 17728227000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -1578030000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 298630000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Investments In Other Ventures Under Equity Method: 56619000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 669322000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 5319000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 1835000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 7154000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 56619000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 13196000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 11609656000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Minority Interests: 0.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Net Debt: 2022149000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income: 1934934000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1934934000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1934935000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1934934000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1934934000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 2607747000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1934935000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -175286000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Interest Income: -201144000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -391233000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -1242877000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -1242900000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -201144000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 100000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -1000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Net PPE: 9885724000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -1021283000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -1242877000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 15168563000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 788376000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 53608000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 94381000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 3442877000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Normalized Income: 1934329274.38
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 2501154000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Operating Income: 2795088000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Operating Revenue: 19360045000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 90626008.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: 52000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 75800000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 27425000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 15131700000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 398497000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 26345000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 201144000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: -1000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 100000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 493000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 813797000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Payable: 210427000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Properties: 9238800000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 66211000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 509901000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Other Special Charges: 580000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Payables: 3641321000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 54976000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 410564000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Pretax Income: 2607748000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 15000000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -175286000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -391233000.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -1021300000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 1938342000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 12539679000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 625427000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 39964000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 39964000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Research And Development: 139605000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 723000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 8893950000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 737537000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 881930000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 90626008.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: -580000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 15584866000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 15168563000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 210274.38
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 672813000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 0.00
AARTIPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -623827000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 22440238000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 15586701000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 2153128000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 15584866000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 16564957000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 6855372000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 10810179000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 849138000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 14185000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 35150000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 815000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 815000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1402611000.00
AARTIPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 5623825000.00
AARTIPHARM.NS income_statement (annual, 2023-03-31) — Write Off: 59000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 3896311000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 18155052000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 3783169000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 5193444000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -5368482000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 4405754000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -22438000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Amortization: 12700000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 12700000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 311196000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 90626008.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 23.93
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 121212000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1947005000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -1987851000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 211505000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 453130000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 236349000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 940326000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -181252000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 236349000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -396636000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 433484000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -1255354000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -1218506000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 115137000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 453130000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 17570392000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 907573000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 11130624000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 13456410000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 44914000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 2640647000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 2685561000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 6943891000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 63100000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 719653000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 732353000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 732353000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 719653000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 90633564.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 23.93
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 2169021000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 1430000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 321000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 3177067000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 3909420000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 236349000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 97235000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 2966470000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 175695000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -5827000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -5506000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 123874000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 770547000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 5215882000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 16422972000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 7024428000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 172147000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 172147000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 30419000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 30419000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -172147000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 30419000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 6428583000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 20211427000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -2145644000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 311196000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Investments In Other Ventures Under Equity Method: 56599000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 779384000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 166591000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 388000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 166979000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 56599000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 60600000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 12789010000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Net Debt: 2404686000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 2169021000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 2169021000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 2169021000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 2169021000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 2169021000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 3004919000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 2169021000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -431809000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: -141728000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -188533000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 499935000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 0.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -141728000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -1000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 5506000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 11054490000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -1556042000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 499935000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 16799845000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 1079200000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 60590000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 113290000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 3897190000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 2160193102.14
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 2163546000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 3128117000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 18155052000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 90626008.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 3000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 53700000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 2284000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 752741000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 21406000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 141728000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: -4000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: -1000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 5980000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 851663000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 152567000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 10146900000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 121125000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 703977000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Other Special Charges: -190000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 3937166000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 63137000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 734230000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 3004920000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 10676000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -431809000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -194039000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -1556042000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2173383000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 11130624000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 732353000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 11593000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 11593000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Research And Development: 83701000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 4271000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 10857668000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 5506000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 679712000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 803586000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 90626008.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 190000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 17570392000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 16799845000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 3402102.14
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 835899000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.28
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 34428000.00
AARTIPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -569370000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 25821051000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 17570780000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 2852540000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 17570392000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 15026935000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 8250659000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 12364641000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 1306768000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 0.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 12230000.00
AARTIPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 12230000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1288730000.00
AARTIPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 6512519000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 3335265000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 4334058000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 517883000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 189656000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 453130000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 408079000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 1041298000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 453130000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 18567267000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 1159917000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 13766735000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 61516000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 2659447000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 2720963000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 6834873000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 127907000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 917405000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 12283479000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 7197960000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 22242309000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 517883000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 128140000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 1015595000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 1143735000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 70491000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 3266963000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 12283479000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 17649862000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 1148753000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 90626008.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 1126602000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 224261000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 18114137000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 899599000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 208059000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 11123562000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 9769000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 633219000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 3335265000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 90626008.00
AARTIPHARM.NS income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 18567267000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 17649862000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 57048000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 27765119000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 19582862000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 3864698000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 18567267000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 9197852000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 13998384000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 2362979000.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 0.00
AARTIPHARM.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 6931862000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 6609548000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 1813155000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 21150745000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 5637770000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 2778304000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 2778304000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 5754047000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 5754047000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -6147149000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -6147149000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 4410078000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 4410078000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -28070000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -28070000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Amortization: 52604000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 52604000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 235834000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 235834000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 90620359.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 90605949.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 30.06
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 9.75
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 236349000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 2128610000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 2128610000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -4438783000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 167629000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 167629000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 453173000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 453173000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 67337000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 67337000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 555725000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 555725000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -317191000.00